FORTUNE ANNOUNCED FORTUNE CHINA 500 RANKINGS, SERES HAD THE BIGGEST LEAP IN 2025 RANKINGS DRIVEN BY AITO BRAND GROWTH
CHONGQING, China, Aug. 1, 2025 /PRNewswire/ -- SERES has emerged as this year's biggest mover on the 2025 Fortune China 500 list, vaulting to 169th place, a jump of 235 spots from last year's 404th position. This dramatic rise underscores SERES' rapid growth in the highly competitive new energy vehicle (NEV) market. In 2024, SERES' revenue surged to RMB 145.2 billion (approx. US$20.2 billion), up 305% year on year, while net profit attributable to shareholders reached RMB 5.95 billion. The company's annual NEV sales reached 420,000 units, an increase of more than 182%, driving its gross profit margin for the NEV business to 26.21%—a new record high.
Fortune highlighted that amid rapid NEV sector growth and intensifying competition, SERES' success was driven by its close collaboration with partners, enabling continuous product innovation and operational excellence.
AITO Brand Fuels Growth
AITO, the luxury NEV brand founded in 2021, has been a core growth driver. In just 40 months, AITO achieved over 700,000 cumulative deliveries, setting a new record for delivery speed among luxury NEV brands in China including over 200,000 units delivered of the flagship model AITO M9 and deliveries of the recently launched AITO M8 already surpassing 40,000 units. In addition, the new AITO M7 series has maintained its position as the top-selling model in the highly competitive RMB 300,000 (approx. US$42,000) segment from 2024 to the present, setting a new record for Chinese luxury new energy brands.
These milestones demonstrate the brand's ability to deliver advanced intelligent luxury experiences while accelerating its expansion in both domestic and overseas markets. With its strong manufacturing capabilities, deep collaboration on intelligent vehicle technologies, and a growing product portfolio, SERES is well-positioned to further strengthen its leadership in China's NEV market and make significant strides globally.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
7 hours ago
- Korea Herald
FM Cho says Lee-Trump summit unlikely to be delayed to next month
Foreign Minister Cho Hyun said Sunday last-minute coordination to set a date for a summit between President Lee Jae Myung and US President Donald Trump is under way, noting the envisioned meeting will not be delayed to next month. Last week, Trump announced that Lee will visit the White House in two weeks, as he announced Washington has agreed to lower "reciprocal" tariffs on South Korea to 15 percent from the proposed 25 percent in return for massive investments and market opening. Cho made the remark as he arrived in Seoul after back-to-back visits to the United States and Japan for his first talks with his counterparts since the launch of the Lee administration in June. Cho said his US visit, which included meetings with senior officials, including Secretary of State Marco Rubio, served as an occasion to reaffirm Washington's commitment to extended deterrence. "(We) reaffirmed the steadfast South Korea-US combined response posture, and extended deterrence and agreed to continue to cooperate going forward," Cho said. When asked about the Trump administration's push to "modernize" the alliance, Cho said the move involves taking various necessary measures, such as strengthening defense capabilities in the face of a stern international security environment, while brushing off concerns such push will affect Seoul's ties with China. Cho said in-depth talks over a possible role change of US troops in South Korea did not take place, saying the two sides agreed to discuss additional matters in working-level talks going forward. Addressing the possibility the US may seek to reset security issues following the tariff deal, Cho said he believes the allies could reach mutually beneficial agreements in the defense sector. (Yonhap)
Korea Herald
13 hours ago
- Korea Herald
Foreign money returns to Kospi, piling into Samsung
Analysts forecast Kospi's rally to take pause in August amid market correction Foreign investors net purchased shares of over 6 trillion won ($4.3 billion) on the benchmark Kospi in July, driven largely by a massive 3.5 trillion won buying spree on the country's leading chipmaker, Samsung Electronics. Offshore investors bought a net 6.28 trillion won worth of local stocks on the main bourse Kospi in July, according to the data from the bourse operator Korea Exchange. It was the largest amount since the 7.86 trillion won net buying in February 2024. Since turning to a net buying stance in May, foreign investors have been scooping up shares on the Kospi for three consecutive months. Samsung Electronics was the top pick, drawing 3.5 trillion won in net foreign purchases, accounting for 56 percent of the monthly total. Giving further buying momentum was news that the company would manufacture AI chips for Tesla under a multiyear $16.5 billion deal, stoking hopes of a rebound in its loss-making foundry business. Hanwha Ocean followed, buoyed by expectations surrounding the Korea-US trade deal, with offshore investors net purchasing shares worth 858 billion won. The shipbuilder under the defense-to-energy conglomerate Hanwha Group is expected to anchor the Korea-US shipbuilding initiative 'Make American Shipbuilding Great Again.' Shares of SK Square (457 billion won), Isu Petasys (329 billion won) and Hanwha Aerospace (249 billion won) trailed behind as the next most purchased stocks. Marking a contrast with the buying rally for Samsung Electronics, offshore investors offloaded 193.1 billion won worth of SK hynix shares last month, following a bearish forecast from global banking giant Goldman Sachs. Naver was the most sold stock by foreigners during the period, as they dumped 668.2 billion won worth of shares last month. Major net sold stocks included Doosan Enerbility (243.8 billion won), Samsung SDI (206.8 billion won), Kakao Pay (184.5 billion won) and KB Financial Group (159.8 billion won). Meanwhile, the Kospi sank to 3,119.41 on Friday, down 3.88 percent from the previous session, marking its sharpest single-day drop in two months. The stock market was dampened by the government's tax code revision plan and the uncertainty associated with the US tariff talks. On the day, foreign investors offloaded shares worth 656 billion won on the Kospi. 'Investor sentiment weakened as expectations for US rate cuts receded. Foreign investors posted net selling of around 1 trillion won in both the spot and futures markets amid a stronger dollar,' analyst Park Ki-hoon from Korea Investment & Securities explained. 'The market experienced a sharp correction as a series of expectations quickly unraveled amid heightened macro uncertainty both at home and abroad,' said Lee Kyung-min of Daishin Securities. Despite the Kospi's bullish run in recent months, analysts anticipate a period of elevated volatility in August as the index steps into a phase of valuation correction. 'The conclusion of the Korea-US tariff negotiations, diminished expectations for US rate cuts, and lowered hopes for tax reform are factors weighing on the stock market," said Na Jeong-hwan, an analyst at NH Investment & Securities, projecting the Kospi to trade between 3,000 and 3,300 points this week. 'With a lack of earnings momentum in the domestic market, a short-term correction appears necessary. Volatility is expected to increase in August,' said Kyobo Securities analyst Kim Joon-woo, suggesting the Kospi could inch down to as low as 2,900 points this month.
Korea Herald
16 hours ago
- Korea Herald
LG deepens biohealth push with investment in US anticancer biotech
LG Group is accelerating its push into the biohealth sector by investing in Strand Therapeutics, a US-based developer of messenger RNA-based cancer therapies. LG recently participated as a Series B investor in Strand Therapeutics through its venture capital arm, LG Technology Ventures, according to industry sources on Sunday. Headquartered in Cambridge, Massachusetts, the biopharma firm was founded in 2017 by a group of synthetic biologists from the Massachusetts Institute of Technology. The firm specializes in programming cells within the body to produce precise amounts of antigens at the right time to treat cancer, autoimmune conditions and rare diseases. With this latest investment, LG Technology Ventures' cumulative funding in biotech startups is estimated to have surpassed $50 million. The move aligns with LG's strategic emphasis on 'ABC' industries ― artificial intelligence, bio and clean tech ― as future growth engines. The conglomerate is focusing on creating cross-sector synergies by integrating advanced technologies with health care and sustainability-driven ventures. The group's Chair Koo Kwang-mo underscored the importance of AI and biotechnology in his New Year's address, saying, 'We are striving for a future where loved ones can live longer, healthier lives through breakthrough therapies.' In February, LG made a follow-up investment in ADARx Pharmaceuticals, a San Diego-based company developing first-in-class treatments for rare metabolic diseases through appetite suppression. LG has also invested in several other biohealth innovators, including: Aetion, Eko Health and Accellex. To strengthen its research and development capabilities, LG is increasingly integrating AI with biotechnology. Earlier this month, LG AI Research, the artificial intelligence arm of LG Group, unveiled Exaone Pass 2.0, an AI diagnostic model capable of identifying cancer in under one minute.
